Exelixis' Cabozantinib Targets Particularly Sick Thyroid Cancer Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
Progression-free survival benefit in Phase III trial of rare medullary thyroid cancer was even better than expected, though full safety results are needed to flesh out the drug's profile.